Treatment of hypertension in peripheral arterial disease

Cochrane Database of Systematic Reviews

Volumn 2013, Issue 12, 2013, Pages

  Lane, Deirdre A ^a   Lip, Gregory Y H ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ATENOLOL; DOXAZOSIN; HYDROCHLOROTHIAZIDE; METOPROLOL; NEBIVOLOL; PERINDOPRIL; PLACEBO; RAMIPRIL; TELMISARTAN; THIAZIDE DIURETIC AGENT; TRANDOLAPRIL; VERAPAMIL; ANTIHYPERTENSIVE AGENT;

ALL CAUSE MORTALITY; AMPUTATION; ANGIOPLASTY; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL WALL THICKNESS; BLOOD PRESSURE MEASUREMENT; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CLAUDICATION; DISEASE EXACERBATION; DRUG EFFECT; HEART INFARCTION; HUMAN; HYPERTENSION; LEG ISCHEMIA; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; REVIEW; SYSTEMATIC REVIEW; FEMALE; INTERMITTENT CLAUDICATION; MALE; META ANALYSIS; PERIPHERAL VASCULAR DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTIHYPERTENSIVE AGENTS; FEMALE; HUMANS; HYPERTENSION; INTERMITTENT CLAUDICATION; MALE; PERIPHERAL VASCULAR DISEASES; RANDOMIZED CONTROLLED TRIALS AS TOPIC;

EID: 84897368186     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD003075.pub3     Document Type: Review

References (126)

1. Hoogerbrugge N, de Groot E, de Heide LH, de Ridder MA, Birkenhageri JC, Stijnen T, et al.Doxazosin and hydrochlorothiazide equally affect arterial wall thickness in hypertensive males with hypercholesterolaemia (the DAPHNE study). Doxazosin Atherosclerosis Progression Study in Hypertensives in the Netherlands. Netherlands Journal of Medicine 2002;60(9):354-61.
2. Diehm C, Pittrow D, Lawall H, for the study group. Effect of nebivolol vs. hydrochlorothiazide on the walking capacity in hypertensive patients with intermittent claudication. Journal of Hypertension 2011;29(7):1448-56.
3. Ostergren J, Sleight P, Dagenais G, Danisa K, Bosch J, Qilong Y, et al.for the HOPE study investigators. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. European Heart Journal 2004;25(1):17-24.
4. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology 1996;12(2):127-37.
5. Yusuf S, Dagenais G, Pogue J, Bosch J, Sleight P. Vitamin E supplementation and cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. New England Journal of Medicine 2000;342(3):154-60.
6. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. New England Journal of Medicine 2000;342(3):145-53.
7. Bavry AA, Anderson D, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al.Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: Findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55(1):48-53.
8. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli FH, et al.INVEST Investigators. A calcium antagonist vs a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolspril Study (INVEST): A randomised controlled trial. JAMA 2003;290(21):2805-16.
9. Pepine CJ, Handberg-Thurmond E, Marks RG, Conlon M, Cooper-DeHoof R, Volkers P, et al.Rationale and design of the International Verapamil SR/Trandolapril Study (INVEST): An internet-based randomised trial in coronary artery disease patients with hypertension. Journal of the American College of Cardiology 1998;32(5):1228-37.
10. Espinola-Klein C, Weisser G, Jagodzinski A, Savvidis S, Warnholtz A, Ostad MA, et al.β-blockers in patients with intermittent claudication and arterial hypertension: Results from the nebivolol or metoprolol in arterial occlusive disease trial. Hypertension 2011;58(2):148-54.
11. Overlack A, Adamczak M, Bachmann W, Bonner G, Bretzel RG, Derichs R, et al.ACE-inhibition with perindopril in essential hypertensive patients with concomitant diseases. The Perindopril Therapeutic Safety Collaborative Research Group. American Journal of Medicine 1994;97(2):126-34.
12. Schweizer J, Kirch W, Koch R, Hellner G, Uhlmann K. Effect of high dose verapamil on restenosis after peripheral angioplasty. Journal of the American College of Cardiology 1998;31(6):1299-305.
13. Zankl AR, Ivandic B, Andrassy M, Volz HC, Krumsdorf U, Blessing E, et al.Telmisartan improves absolute walking distance and endothelial function in patients with peripheral artery disease. Clinical Research in Cardiology 2010;99(12):787-94.
14. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW. The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. New England Journal of Medicine 1998;338(10):645-52.
15. Estacio RO, Savage S, Nagel NJ, Schrier RW. Baseline characteristics of participants in the Appropriate Blood Pressure Control in Diabetes trial. Controlled Clinical Trials 1996;17(3):242-57.
16. Mehler PS, Coll JR, Estacio R, Esler A, Schrier RW, Hiatt WR. Intensive blood pressure control reduces the risk of cardiovascular events in patients with peripheral arterial disease and type 2 diabetes. Circulation 2003;107(5):753-6.
17. Ahimastos AA, Dart AM, Lawler A, Blombery PA, Kingwell BA. Reduced arterial stiffness may contribute to angiotensin-converting enzyme inhibitor induced improvements in walking time in peripheral arterial disease patients. Journal of Hypertension 2008;26(5):1037-42.
18. Ahimastos AA, Lawler A, Reid CM, Blombery PA, Kingwell BA. Brief communication: ramipril markedly improves walking ability in patients with peripheral arterial disease: a randomized trial. Annals of Internal Medicine 2006;144(9):660-4.
19. Ahimastos AA, Natoli AK, Lawler A, Blombery PA, Kingwell BA. Ramipril reduces large-artery stiffness in peripheral arterial disease and promotes elastogenic remodeling in cell culture. Hypertension 2005;45(6):1194-9.
20. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, et al.ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005;366(9489):895-906.
21. Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, et al.Rationale, design, methods and baseline demography of participants of the Anglo-Scandinavian Cardiac Outcomes Trial. ASCOT investigators. Journal of Hypertension 2001;19(6):1139-47.
22. Bernardi D, Bartoli P, Ferreri A, Geri AB, Ieri A. Assessment of captopril and nicardipine effects on chronic occlusive arterial disease of the lower extremity using Doppler ultrasound. Angiology 1988;39(11):942-52.
23. Bogaert MG, Clement DL. Lack of influence of propranolol and metoprolol on walking distance in patients with chronic intermittent claudication. European Heart Journal 1983;4(3):203-4.
24. Bostrom PA, Janzon L, Ohlsson O, Westergren A. The effect of beta-blockade on leg blood flow in hypertensive patients with intermittent claudication. Angiology 1986;37(3 Pt 1):149-53.
25. Branchereau A, Rouffy J. Double-blind randomized controlled trial of ifenprodil tartrate versus placebo in chronic arterial occlusive disease of the legs at stage II of the Leriche and Fontaine classification. Journal des Maladies Vasculaires 1995;20(1):21-7.
26. Brown MJ, Castaigne A, de Leeuw PW, Mancia G, Rosenthal T, Ruilope LM. Study population and treatment titration in the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Journal of Hypertension 1998;16(12 Pt 2):2113-6.
27. Casiglia E, Petucco S, Pessina AC. Antihypertensive efficacy of amlodipine and enalapril and effects on peripheral blood flow in patients with essential hypertension and intermittent claudication. Clinical Drug Investigation 1997;13 Suppl 1:97-101.
28. Coto V, Cocozza M, Oliviero U, Lucariello A, Picano T, Coto F, et al.Clinical efficacy of picotamide in long-term treatment of intermittent claudication. Angiology 1989;40(10):880-5.
29. Coto V, Oliviero U, Cocozza M, Lucariello A, Picano T, Coto F. A comparative trial of ketanserin and nifedipine in hypertension and obstructive peripheral arteriopathy. Advances in Therapy 1991;8(3):133-40.
30. Diehm C, Jacobsen O, Amendt K. The effects of tertatolol on lipid profile. Cardiology 1993;83 Suppl 1:32-40.
31. Domschky K, Nelson M, Dammhayn B, Terjung E. Multicentre double blind study concerning flunarizine versus placebo in patients with cerebral and peripheral circulatory disorders. Medizinische Welt 1977;28(23):1062-4.
32. Gastmann U, Lehmann M, Staiger J, Keul J. Influence of the calcium antagonist nisoldipin on the sympathetic activity and the energy metabolism at rest and during walking stress in patients with peripheral arterial of the legs and healthy control subjects [Abstract only]. Zeitschrift fur Kardiologie 1987;76 Suppl 2:13.
33. Hiatt WR, Stoll S, Nies AS. Effect of beta-adrenergic blockers on the peripheral circulation in patients with peripheral vascular disease. Circulation 1985;72(6):1226-31.
34. Ingram DM, House AK, Thompson GH, Stacey MC, Castleden WM, Lovegrove FT. Beta-adrenergic blockade and peripheral vascular disease. Medical Journal of Australia 1982;1(12):509-11.
35. Jageneau A, Haag F. Flunarizine versus placebo in patients with circulatory disorders of the lower extremities: double blind study. Medizinische Welt 1977;28(23):1050-5.
36. Kalus U, Jung F, Scheurer K, Koscielny J, Radtke H, Kiesewetter H, et al.The alpha and beta blocker carvediol in the treatment of hypertensive patients with POAD. Clinical Hemorheology 1995;15(5):570.
37. Klieber M, Resch F. Comparative studies of the effect of a cardioselective and a noncardioselective beta-blocker on peripheral circulation in patients with arterial occlusive disease [Vergleichende Untersuchengen uber die Werkung eines Kardioselektiven und eines Nichtkardioselektiven Betablockers auf die Periphere Durchblutung von Patienten mit Arterieller Verschlusskrankheit]. Weiner Klinische Wochenschrift 1986;98(3):70-3.
38. Larsen OA, Lassen NA. Medical treatment of occlusive arterial disease of the legs. Walking exercise and medically induced hypertension. Angiologica 1969;6(5):288-301.
39. Laurent S, Becquemont L, Laloux B, Asmar R, Hugue C, Vayssairat M, et al.Haemodynamic effects of chronic treatment by cilazapril in normotensive patients with obliterative arterial disease of the lower limbs [Effets hemodynamiques d'un traitement chronique par le cilazapril chez les malades normotendus atteints d'arteriopathie obliiterante des membres inferieurs]. Archives des Maladies du Coeur et des Vaisseaux 1994;87(8):987-90.
40. Leeman M, Degaute JP. Invasive haemodynamic evaluation of sublingual captopril and nifedipine in patients with arterial hypertension after abdominal aortic surgery. Critical Care Medicine 1995;23(5):843-7.
41. Lepantalo M, Totterman KJ. Effect of long term beta-adrenergic-blockade on calf blood flow in hypertensive patients. Clinical Physiology 1983;3(1):35-42.
42. Lepantalo M, von Knorring J. Walking capacity of patients with intermittent claudication during chronic antihypertensive treatment with metoprolol and methyldopa. Clinical Physiology 1984;4(4):275-82.
43. Lepantalo M. Beta blockade and intermittent claudication. Acta Medica Scandinavica. Supplementum 1985;700:1-48.
44. Lepantalo M. Chronic effects of labetolol, pindolol and propranolol on calf blood flow in intermittent claudication. Clinical Pharmacology and Therapeutics 1985;37(1):7-12.
45. Lepantalo M, Lindstrom BL, Totterman KJ. Adrenoreceptor blocking drugs and cold feet in intermittent claudication. Vasa 1986;15(2):135-7.
46. Lepantalo M, Aromaa A, Klaukka T, Lukkari E. Does beta-blockade provoke intermittent claudication?. Acta Medica Scandinavica 1985;218(1):35-9.
47. Liakishev AA. Telmisartan, ramipril, or both in patients at high risk for vascular events. Results of the ONTARGET trial [Russian]. Kardiologiia 2008;48(5):72.
48. Lievre M, Azoulay S, Lion L, Morand S, Girre JP, Boissel JP. A dose-effect study of beraprost sodium in intermittent claudication. Journal of Cardiovascular Pharmacology 1996;27(6):788-93.
49. Dahlöf B, Devereux R, de Faire U, Fyhrquist F, Hedner T, Ibsen H, et al.The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group. American Journal of Hypertension 1997;10(7 Part 1):705-13.
50. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, et al.LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002;359(9311):995-1003.
51. Liu Y, Opitz-Gress A, Rott A, Liewald F, Sunder-Plassmann L, Lehmann M, et al.Effect of felodipine on regional blood supply and collateral vascular resistance in patients with peripheral arterial occlusive disease. Vascular Medicine 1997;2(1):13-8.
52. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7(3):176-83.
53. Natali J, Kieny R, Le Bas P, Benhamou M, Molkhou JM. Ifenprodil tartrate in the treatment of occlusive arteriopathies of the lower limbs. Results of a prospective double-blind controlled multi-centre trial [Le tartrate d'ifenprodil dans le traitement des arteriopathies obliterantes des membres inferieures]. Annales de Cardiologie et d'Angeiologie 1989;38(6):339-42.
54. Nelson M, DeWitz G, Dom J, Hoerig CH. Trial of the activity of Sibelium (flunarizine) in circulatory disorders. Medizinische Welt 1978;29(29-30):1175-81.
55. Novo S, Pinto A, Galati D, Giannola A, Forte G, Strano A. Effects of chronic administration of selective betablockers on peripheral circulation of the lower limbs in patients with essential hypertension. International Angiology 1985;4(2):229-34.
56. Novo S, Alaimo G, Abrignani MG, Giordano U, Avellone G, Pinto A, et al.Effects of ketanserin on blood pressure, peripheral circulation and haemocoagulative parameters in essential hypertensives with or without arteriosclerosis obliterans of the lower limbs. International Journal of Clinical Pharmacology Research 1986;6(3):199-211.
57. Novo S, Abrignani MG, Pavone G, Zamueli M, Pernice C, Geraci AM, et al.Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. International Angiology 1996;15(2):169-74.
58. Bohm M, Baumhakel M, Teo K, Sleight P, Probstfield J, Gao P, et al.ONTARGET/TRANSCEND Erectile Dysfunction Substudy Investigators. Erectile dysfunction predicts cardiovascular events in high-risk patients receiving telmisartan, ramipril, or both: The ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial/Telmisartan Randomised AssessmeNt Study in ACE iNtolerant subjects with cardiovascular Disease (ONTARGET/TRANSCEND) Trials. Circulation 2010;121(12):1439-46.
59. Cowan BR, Young AA, Anderson C, Doughty RN, Krittayaphong R, Lonn E, et al.ONTARGET Investigators. Left ventricular mass and volume with telmisartan, ramipril, or combination in patients with previous atherosclerotic events or with diabetes mellitus (from the ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial (ONTARGET). American Journal of Cardiology 2009;104(11):1484-9.
60. Teo K, Yusuf S, Sleight P, Anderson C, Mookadam F, Ramos B, et al.ONTARGET/TRANSCEND Investigators. Rationale, design, and baseline characteristics of 2 large, simple, randomized trials evaluating telmisartan, ramipril, and their combination in high-risk patients: the Ongoing Telmisartan Alone and in Combination with Ramipril Global Endpoint Trial/Telmisartan Randomized Assessment Study in ACE Intolerant Subjects with Cardiovascular Disease (ONTARGET/TRANSCEND) trials. American Heart Journal 2004;148(1):52-61.
61. The ONTARGET Investigators, Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al.Telmisartan, ramipril, or both in patients at high risk for vascular events. New England Journal of Medicine 2008;358(15):1547-59.
62. Yu LT, Zhu J, Tan HQ, Wang GG, Teo KK, Liu S, et al.Telmisartan, ramipril, or both in high-risk Chinese patients: analysis of ONTARGET China data. Chinese Medical Journal 2011;124(12):1763-8.
63. Kostis JB, Cobbe S, Johnston C, Ford I, Murphy M, Weber M, et al.OPERA Study Group. Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events. Design of the Omapatrilat in Persons with Enhanced Risk of Atherosclerotic events (OPERA) trial. American Journal of Hypertension 2002;15(2 Pt 1):193-8.
64. Panzner B, Haringer E. Efficacy and tolerability of celiprolol and enalapril in patients with essential hypertension. Journal of Drug Development 1992;5(2):83-7.
65. POISE study group. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. Lancet 2008;371(9627):1839-47.
66. Reichert N, Shibolet S, Adar R, Gafni J. Controlled trial of propranolol in intermittent claudication. Clinical Pharmacology and Therapeutics 1975;17(5):612-5.
67. Roberts DH, Tsao Y, McLoughlin GA, Breckenridge A. Placebo-controlled comparison of captopril, atenolol, labetalol and pindolol in hypertension complicated by intermittent claudication. Lancet 1987;2(8560):650-3.
68. Roberts DH, Tsao Y, Linge K, Chatlani PT, McLoughlin GA, Breckenridge AM. Double-blind comparison of captopril or nifedipine in hypertension complicated by intermittent claudication. British Journal of Clinical Pharmacology 1988;25(5):631P-2P.
69. Roberts DH, Tsao Y, Linge K, McLoughlin GA, Breckenridge A. Double-blind comparison of captopril with nifedipine in hypertension complicated by intermittent claudication. Angiology 1992;43(9):748-56.
70. Rouffy J, Djian F, Barret A, Branchereau A, Chevalier JM, Cristol R, et al.Ifenprodil tartrate for the treatment of chronic obliterating arteriosclerosis of the lower limbs with intermittent claudication. A multicentre, prospective, randomised, double-blind trial versus placebo [Le tartrate d'ifenprodil dans le traitement de l'arteriopathie chronique obliterante des membres inferieurs. Au stade de la claudication intermittente]. Semaines des Hopitaux 1989;65(33):2071-6.
71. Schweizer J, Kaulen R, Altman E, Nierade A, Nanning T. Are beta-blockers generally contraindicated in patients with peripheral arterial occlusive disease? [Sind Betablocker bei Patienten mit Peripherer Arterieller Verschlusskrankheit Generell Kontraindiziert?]. Zeitschrift fur Kardiologie 1996;85(3):193-7.
72. Schweizer J, Kaulen R, Nierade A, Altman E. Beta blockers and nitrates in patients with peripheral arterial occlusive disease: long term findings. Vasa 1997;26(1):43-6.
73. Siniscalchi N, De Nicola A, Misso L, Cerciello T, Carbone L, Molisso A. Treatment and monitoring of obstructive peripheral arterial disease in elderly with systolic hypertension. International Angiology 1993;12:76.
74. Smith RS, Warren DJ. Effect of beta-blocking drugs on peripheral blood flow in intermittent claudication. Journal of Cardiovascular Pharmacology 1982;4(1):2-4.
75. Solomon SA, Ramsay LE, Yeo WW, Parnell L, Morris-Jones W. Beta blockade and intermittent claudication: placebo controlled trial of atenolol and nifedipine and their combination. BMJ 1991;303(6810):1100-4.
76. Spence JD, Arnold MO, Munoz CE, Vishwanatha A, Huff M, Derose G, et al.Angiotensin-converting enzyme inhibition with cilazapril does not improve blood flow, walking time, or plasma lipids in patients with intermittent claudication. Journal of Vascular Medicine and Biology 1993;4(1):23-8.
77. Staessen AJ. Flunarizine and cinnarizine in pharmacotherapy of circulatory disturbances. Ars Medici Internationaal Tijdschrift voor Praktische Therapie 1978;7(5):433-45.
78. Stumpe KO, Overlack A. A new trial of the efficacy, tolerability and safety of angiotensin-converting enzyme inhibition in mild systemic hypertension with concomitant diseases and therapies. Perindopril Therapeutic Safety Study Group (PUTS). American Journal of Cardiology 1993;71(17):32E-7E.
79. Stumpe KO, Ludwig M, Heagerty AM, Kolloch RE, Mancia G, Safar M, et al.Vascular wall thickness in hypertension: the Perindopril Regression of Vascular Thickening European Community Trial: PROTECT. American Journal of Cardiology 1995;76(15):50E-4E.
80. Sutton-Tyrell K, Alcorn HG, Herzog H, Kelsey SF, Kuller LH. Morbidity, mortality, and antihypertensive treatment effects by extent of atherosclerosis in older adults with isolated systolic hypertension. Stroke 1995;26(8):1319-24.
81. Svendsen TL, Jelnes R, Tonnesen KH. Is adrenergic betareceptor blockade contraindicated in patients with intermittent claudication?. Acta Medica Scandinavica. Supplementum 1985;217(s693):129-32.
82. Svendsen TL, Jelnes R, Tonnesen KH. The effects of acebutolol and metoprolol on walking distances and distal blood pressure in hypertensive patients with intermittent claudication. Acta Medica Scandinavica 1986;219(2):161-5.
83. Takeda K, Ohshima M, Matsumoto S, Yagi T, Morigchi J, Takanashi Y. Effects of one-year treatment with calcium channel blocker or angiotensin II receptor blocker on function and stiffness of left ventricle, central and peripheral arteries in patients with essential hypertension. Therapeutic Research 2010;31(3):351-62.
84. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hansson L, et al.VALUE trial group. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet 2004;363(9426):2022-31.
85. Mann J, Julius S. The Valsartan Antihypertensive Long-term Use Evaluation (VALUE) trial of cardiovascular events in hypertension. Rationale and design. Blood Pressure 1998;7(3):176-83.
86. Zanchetti A, Julius S, Kjeldsen S, McInnes GT, Hua T, Weber M, et al.Outcomes in subgroups of hypertensive patients treated with regimens based on valsartan and amlodipine: An analysis of findings from the VALUE trial. Journal of Hypertension 2006;24(11):2163-8.
87. Van de Ven LL, Van Leeuwen JT, Smit AJ. The influence of chronic treatment with beta-blockade and angiotensin converting enzyme inhibition on the peripheral blood flow in hypertensive patients with and without concomitant intermittent claudication. A comparative cross-over trial. Vasa 1994;23(4):357-62.
88. Weibull H, Bergentz S, Bergqvist D, Hulthen L, Manhem P, Jonsson K, et al.Percutaneous transluminal angioplasty vs reconstructive renovascular surgery in atherosclerotic unilateral renal artery stenosis - a prospective randomised study. Journal of Vascular Surgery 1992;15(6):1058.
89. Winterfeld HJ, Strangfeld D, Siewert H, Schmidt HH, Mederacke W. Behavior of blood pressure and peripheral hemodynamics in interval therapy in untreated and propranolol-treated patients with arterial circulatory disorders of the lower extremities]. [German]. Zeitschrift fur die Gesamte Innere Medizin und Ihre Grenzgebiete 1984;39(18):447-50.
90. Ahimastos AA, Walker PJ, Askew C, Leicht A, Pappas E, Blombery P, et al.Effect of ramipril on walking times and quality of life among patients with peripheral artery disease and intermittent claudication: a randomized controlled trial. JAMA 2013;309(5):453-60.
91. Bauwens F, Duprez D, Van Wassenhove A, Brusselmans F, Clement DL. Localisation and risk factors of peripheral arterial occlusive disease in the female. International Angiology 1989;8(1):32-5.
92. Bavry AA, Anderson RD, Gong Y, Denardo SJ, Cooper-DeHoff RM, Handberg EM, et al.Outcomes among hypertensive patients with concomitant peripheral and coronary artery disease: Findings from the INternational VErapamil-SR/Trandolapril STudy. Hypertension 2010;55(1):48-53.
93. Binaghi F, Fronteddu PF, Cannas F, Caredda E, Uras A, Garau P, et al.Prevalence of peripheral arterial occlusive disease and associated risk factors in a sample of southern Sardinian population. International Angiology 1994;13(3):233-45.
94. Bowlin SJ, Medalie JH, Flocke SA, Zyzanski SJ, Yaari S, Goldbourt U. Intermittent claudication in 8343 men and 21-year specific mortality follow-up. Annals of Epidemiology 1997;7(3):180-7.
95. Breckenridge A, Roberts D, Walley T. Different vasodilating mechanisms - different peripheral effects?. Journal of Cardiovascular Pharmacology 1992;19 Suppl 1:S23-6.
96. Cheng SW, Ting AC, Lau H, Wong J. Epidemiology of atherosclerotic peripheral arterial occlusive disease in Hong Kong. World Journal of Surgery 1999;23(2):202-6.
97. Clement DL, Debuyzere ML. How to treat hypertension in patients with peripheral artery disease. Current Hypertenssion Reports 2007;9:190-5.
98. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, et al.Mortality over a period of 10 years in patients with peripheral arterial disease. New England Journal of Medicine 1992;326:381-6.
99. Dormandy JA, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). Journal of Vascular Surgery 2000;31:S1-S296.
100. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, et al.2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Journal of Hypertension 2013;31:1281-357.
101. Feringa HH, van Waning VH, Bax JJ, Elhendy A, Boersma E, Schouten O, et al.Cardioprotective medication is associated with improved survival in patients with peripheral arterial disease. Journal of the American College of Cardiology 2006;47:1182-7.
102. Fontaine R, Kim M, Kieny R. Surgical treatment for peripheral vascular disease [Die chirurgische Behandlung der peripheren Durchblutungsstörungen]. Helvetica Chirurgica Acta 1954;5/6:499-533.
103. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Prescott RJ, et al.Smoking, lipids, glucose intolerance, and blood pressure as risk factors for peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. American Journal of Epidemiology 1992;135(4):331-40.
104. Fowkes FG, Rudan D, Rudan I, Aboyans V, Denenberg JO, McDermott MM, et al.Comparison of global estimates of prevalence and risk factors for peripheral artery disease in 2000 and 2010: a systematic review and analysis. Lancet 2013;382(9901):1329-40. [DOI: ]
105. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
106. Hirsch AT, Criqui MH, Treat-Jacobson D, Regensteiner JG, Creager MA, Olin JW, et al.Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-24.
107. Hjalmarson A. Effects of beta blockade on sudden cardiac death during acute myocardial infarction and the postinfarction period. American Journal of Cardiology 1997;80(9B):35J-9J.
108. The HOPE Study Investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: the design of a large, simple randomised trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Canadian Journal of Cardiology 1996;12(2):127-37.
109. Pepine CJ, Kowey PR, Kupfer S, Kolloch RE, Benetos A, Mancia G, et al.Predictors of adverse outcome among patients with hypertension and coronary artery disease. Journal of the American College of Cardiology 2006;47:547-51.
110. Johnston KW, Rae M, Steiner G, Kalman PG, Schwartz L, Hill ME, et al.An atherosclerosis risk factor assessment program for patients with peripheral arterial occlusive disease. Annals of Vascular Surgery 1988;2(2):101-7.
111. Kannel WB. Role of blood pressure in cardiovascular morbidity and mortality. Progress in Cardiovascular Diseases 1974;17(1):5-24.
112. Kannel WB. The demographics of claudication and the aging of the American population. Vascular Medicine 1996;1(1):60-4.
113. Makin A, Lip GY, Silverman S, Beevers DG. Peripheral vascular disease and hypertension: a forgotten association?. Journal of Human Hypertension 2001;15(7):447-54.
114. Makin A, Silverman SH, Lip GYH. Peripheral vascular disease and Virchow's triad for thrombogenesis. QJM 2002;95(4):199-210.
115. McGill HC Jr, McMahan CA, Tracy RE, Oalmann MC, Cornhill JF, Herderick EE, et al.Relation of a postmortem renal index of hypertension to atherosclerosis and coronary artery size in young men and women. Pathobiological Determinants of Atherosclerosis in Youth (PDAY) Research Group. Arteriosclerosis Thrombosis and Vascular Biology 1998;18(7):1108-18.
116. Murabito JM, Evans JC, D'Agostino RB Sr, Wilson PW, Kannel WB. Temporal trends in the incidence of intermittent claudication from 1950 to 1999. American Journal of Epidemiology 2005;162:430-7.
117. Novo S, Avellone G, Di Garbo V, Abrignani MG, Liquori M, Panno AV, et al.Prevalence of risk factors in patients with peripheral arterial disease. A clinical and epidemiological evaluation. International Angiology 1992;11(3):218-29.
118. Pande RL, Perlstein TS, Beckman JA, Creager MA. Secondary prevention and mortality in peripheral artery disease: National Health and Nutrition Examination Study, 1999 to 2004. Circulation 2011;124:17-23.
119. Radack K, Deck C. Beta-adrenergic blocker therapy does not worsen intermittent claudication in subjects with peripheral arterial disease. A meta-analysis of randomized controlled trials. Archives of Internal Medicine 1991;151:1769-76.
120. Reunanen A, Takkunen H, Aromaa A. Prevalence of intermittent claudication and its effect on mortality. Acta Medica Scandinavica 1982;211(4):249-56.
121. Simon AC, Levenson J, Maarek B, Bouthier J, Safar ME. Evidence of early changes of the brachial artery circulation in borderline hypertension. Journal of Cardiovascular Pharmacology 1986;8 Suppl 5:S36-8.
122. Singer DR, Kite A. Management of hypertension in peripheral arterial disease: does the choice of drugs matter?. European Journal of Vascular and Endovascular Surgery 2008;35:701-8.
123. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes FG, TASC II Working Group. Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). Journal of Vascular Surgery 2007;45 Suppl S:S5-67.
124. Violi F, Criqui M, Longoni A, Castiglioni C. Relation between risk factors and cardiovascular complications in patients with peripheral vascular disease. Results from the A.D.E.P. study. Atherosclerosis 1996;120(1-2):25-35.
125. Lane DA, Lip GY. Treatment of hypertension in peripheral arterial disease. Cochrane Database of Systematic Reviews 2009, Issue 4. [DOI: ]
126. Lip GYH, Makin AJ. Treatment of hypertension in peripheral arterial disease. Cochrane Database of Systematic Reviews 2003, Issue 2. [DOI: ]